花旗銀行表示，德康醫療的 OTC 血糖監測儀 Stelo 的市場接受度超過了雅培的 Lingo
Citi reports that Dexcom's over-the-counter glucose monitor, Stelo, is outperforming Abbott's Lingo in early uptake. Stelo's earlier launch has contributed to its success. Additionally, app downloads for Dexcom's G7 monitor reached record highs in August, following a slow start earlier in the year. In contrast, Abbott's FreeStyle Libre 3 faced challenges with app downloads in May and June. Year-to-date, Dexcom shares have dropped approximately 47%, while Abbott's shares have increased by about 3%.
Brokerage Citi says early uptake of Dexcom’s (DXCM.O) over-the-counter continuous glucose monitor Stelo is ahead of Abbott’s (ABT.N) Lingo
Stelo is gaining traction benefitting from an earlier launch compared to Lingo - Citi
Adds app data points to a recovery for Dexcom, after the glucose monitor maker slashed its annual revenue forecast
Brokerage says downloads of apps for Dexcom’s continuous glucose monitor G7 went up in August, setting a record high in downloads since launch, after a slower April, May and June with a slight uptick in July
Adds U.S. downloads of apps for ABT’s FreeStyle Libre 3 seem to have struggled in May and June, with a stable July, followed by a more difficult August
DXCM shares have fallen ~47%, while ABT up ~3% YTD
